Anemia and Chronic Heart Failure Implications and Treatment Options by Anand, Inder S.
T
(
r
b
n
v
o
c
b
s
a
o
m
w
m
F
M
R
i
p
A
a
Journal of the American College of Cardiology Vol. 52, No. 7, 2008
© 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00
PSTATE-OF-THE-ART PAPER
Anemia and Chronic Heart Failure
Implications and Treatment Options
Inder S. Anand, MD, FACC, FRCP, DPHIL (OXON)
Minneapolis, Minnesota
Anemia is a common comorbidity in patients with heart failure and is associated with worse long-term out-
comes. Although the cause of anemia in heart failure is unclear, the weight of evidence suggests that renal dys-
function, along with neurohormonal and proinflammatory cytokine activation in heart failure, favors the develop-
ment of anemia of chronic disease, with defective iron utilization, inappropriate erythropoietin production, and
depressed bone marrow function. Similarly, the mechanisms by which anemia worsens heart failure outcomes
are unknown but may be related to increased myocardial workload. If anemia is a mediator and not just a
marker of poor outcomes, correcting anemia could become an important and novel therapeutic target to im-
prove long-term outcomes in such patients. Indeed, several small-sized studies have shown the beneficial effects
of empirically treating anemia in heart failure patients with recombinant erythropoietin and intravenous iron.
However, the ideal threshold at which therapy should be initiated and the extent of correction considered safe
and desirable in the individual patient with heart failure need to be known. These issues become more important
because of increasing safety concerns that recombinant erythropoietin therapy for treating anemia may be associ-
ated with adverse cardiovascular outcomes in patients with chronic kidney disease and may worsen cancer in pa-
tients receiving chemotherapy to treat various types of cancer. Therefore, further prospectively designed studies are
required to address some of these questions. Fortunately, 2 large mortality morbidity trials, TREAT (Trial to Reduce
Cardiovascular Events with Aranesp Therapy) in patients with chronic kidney disease and RED-HF (Reduction of
Events with Darbepoetin alfa in Heart Failure) in heart failure patients, are in progress and are likely to provide defini-
tive answers. (J Am Coll Cardiol 2008;52:501–11) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.04.044P
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ohe annual mortality in patients with chronic heart failure
HF) who are randomized in clinical trials has shown a
emarkable decrease to approximately 8% with the use of
eta-blockers and renin-angiotensin-aldosterone antago-
ists (1). However, the mortality in clinical practice remains
ery high (2). One reason for this disparity is the exclusion
f patients from clinical trials with comorbid conditions that
ontribute to high mortality. Anemia is one such comor-
idity and a novel therapeutic target in HF. This review will
ummarize the magnitude of the problem of anemia in HF
nd examine the factors that are associated with the devel-
pment of anemia and the mechanisms by which anemia
ay worsen HF. The risks and benefits of treating anemia
ith erythropoietin-stimulating agents (ESA), a subject of
uch recent debate, also will be discussed.
rom the VA Medical Center and University of Minnesota Medical School,
inneapolis, Minnesota. Dr. Anand is a member of the Executive Committee of the
ED-HF (Reduction of Events with Darbepoetin alfa in Heart Failure) trial, which
s testing the effects of the erythropoietin-stimulating agent darbepoetin in anemic
atients with heart failure. He has received research support and honoraria from
mgen for this purpose.9
Manuscript received January 31, 2008; revised manuscript received April 9, 2008,
ccepted April 16, 2008.revalence of Anemia in HF
he World Health Organization defines anemia as hemo-
lobin (Hgb) 13.0 g/dl in men and 12.0 g/dl in women
3). Using this definition, Sarnak et al. (4) found 9% (men
%; women 13%) of a normal population ages 45 to 64 years
n the U.S. to have anemia. However, a more appropriate
ge-, gender-, and race-specific definition identified anemia
n approximately 5% of the NHANES (National Health
nd Nutrition Examination Survey) population (5). The
revalence of anemia during HF varies depending on the
efinition and sample selection, as summarized in previous
eviews (6–8). In clinical trials and large HF registries,
he prevalence ranged from 15% to 61% and 14% to 70%
mong hospitalized patients. During the course of 1 year,
ew anemia developed in 9.6% of SOLVD (Studies Of
eft Ventricular Dysfunction) patients (9), 16.9% of
al-HeFT (Valsartan Heart Failure Trial) patients (10),
nd 14.2% of COMET (Carvedilol Or Metoprolol Eu-
opean Trial) patients (11). The prevalence of anemia is
imilar in patients with impaired or preserved left ven-
ricular (LV) function (12–15). In a large community
tudy, 58% of HF patients had anemia of chronic disease,
n the basis of International Classification of Diseases-
th Edition (285.9) code alone (16).
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Anemia and Chronic Heart Failure August 12, 2008:501–11Anemia during HF has been
associated with older age, dia-
betes, chronic kidney disease
(CKD), greater New York Heart
Association (NYHA) functional
class, lower exercise capacity,
worse health-related quality of
life, greater edema, lower blood
pressure, greater use of diuretics,
and greater levels of neurohor-
mones, proinflammatory cyto-
kines, and C-reactive protein
(CRP) (10,17–21). Importantly,
Hgb has a weak inverse relation
to ejection fraction (EF) (10,15),
and an increase in Hgb over time
is associated with a decrease, not
an increase, in EF (10,22).
Potential Causes
of Anemia During HF
Hematinic abnormalities. Serum
vitamin B12 and folic acid levels
are low in only a minority of
anemic patients with HF (23–
5). Malabsorption and aspirin-induced gastrointestinal
leeding can cause iron deficiency. Detailed studies of iron
omeostasis are not available. Lacking standard criteria (i.e.,
ransferrin saturation, soluble transferrin receptor or ferritin
evels), the reported prevalence of iron deficiency has varied
rom 5% to 21% (16,17,23,24,26). In a recent study, 43% of
atients had either low serum iron (8 mol/l) or ferritin
30 g/l), but microcytic anemia was observed in only 6%
atients (27). In contrast, Nanas et al. (28) found depleted
ron stores in the bone marrow of 73% patients despite
ormal serum iron, ferritin, and erythropoietin. The mean
orpuscular volume was at the lower limit of normal,
uggesting that microcytic anemia was not present in all
atients. These findings might be explained by diversion of
ron from the bone marrow to the other reticuloendothelial
tores, where it is not available for erythropoiesis even
hough serum iron and ferritin are normal or increased, a
eature of anemia of chronic disease (29). Therefore, either
bsolute or relative iron deficiency may be more common
han previously thought.
enal dysfunction and impaired erythropoietin produc-
ion. Erythropoietin is produced primarily in the kidney by
pecialized peritubular fibroblasts situated within the cortex
nd outer medulla (30). The primary stimulus for erythro-
oietin production is low PO2 that activates hypoxia-
nducible factor-1 in the peritubular fibroblasts, which
nduces transcription of the erythropoietin gene. The kidney
s very susceptible to hypoxia despite the fact that it receives
early 25% of the cardiac output and uses less than 10% of
Abbreviations
and Acronyms
BNP  brain natriuretic
peptide
BP  blood pressure
CKD  chronic kidney
disease
CRP  C-reactive protein
EF  ejection fraction
ESA  erythropoietin-
stimulating agents
Hct  hematocrit
HF  heart failure
Hgb  hemoglobin
IL  interleukin
IV  intravenous
LV  left ventricular
MLHFQ  Minnesota Living
with Heart Failure
Questionnaire
RBF  renal blood flow
SVR  systemic vascular
resistancehe oxygen delivered. To maintain the osmotic gradient ienerated by the loop of Henle, the arterial and venous
lood vessels supplying it run countercurrent and in close
ontact, which leads to shunt diffusion of oxygen between
he arterial and venous circulations, causing PO2 to decrease
cross the renal parenchyma, reaching around 10 mm Hg at
he tips of the cortical pyramids where the erythropoietin is
roduced (30). This area is very sensitive to small changes in
he PO2, resulting from an imbalance between oxygen
upply and oxygen demand related to increased proximal
ubular sodium reabsorption caused by low renal blood flow
RBF) and glomerular filtration rate.
During HF, RBF is decreased (31), and some renal
ysfunction is common (7,32), but structural renal disease
hat could reduce erythropoietin production is infrequent.
herefore, reduced RBF should increase erythropoietin.
ndeed, erythropoietin is increased, in proportion to the
everity of HF, but is lower than expected for the degree of
nemia, suggesting a blunted erythropoietin production
17,33,34). Studies of the complex relationship between
BF and erythropoietin secretion during HF have been
nconsistent (25,35,36).
nemia and the renin-angiotensin system. Angiotensin
I decreases PO2 by reducing RBF and increasing oxygen
emand, thereby stimulating erythropoietin production.
ngiotensin II also stimulates bone marrow erythroid pro-
enitor cells (37). Angiotensin-converting enzyme inhibi-
ors and angiotensin receptor blockers cause a modest
eduction in Hgb (10,38) by decreasing erythropoietin (39)
nd by preventing the breakdown of the hematopoiesis
nhibitor N-acetyl-seryl-aspartyl-lysyl-proline (40).
roinflammatory state, bone marrow dysfunction, and
nemia of chronic diseases. Tumor necrosis factor-,
nterleukin (IL)-6, and several other proinflammatory cyto-
ines (17,41) and CRP are increased in HF (42) and
nversely related to Hgb (18). Interleukin-6 and tumor
ecrosis factor- inhibit erythropoietin production in the
idney by activating GATA-2 and nuclear factor-B (43),
hich could explain the blunted erythropoietin response in
F. These cytokines also inhibit proliferation of bone
arrow erythroid progenitor cells (44). Indeed, bone mar-
ow in rats with HF show impaired erythropoiesis and have
ecreased number of erythropoietic progenitor cells, but the
echanisms remain unknown (45). Moreover, IL-6 stimu-
ates the production of hepcidin in the liver that blocks
uodenal absorption of iron (29). Furthermore, IL-6 down-
egulates the expression of ferroportin, preventing the re-
ease of iron from body stores (29). Thus, an activated
roinflammatory state, an essential component of anemia of
hronic disease (29), can contribute to the development of
nemia by several mechanisms (Fig. 1).
In 148 patients with stable HF, a specific cause of
nemia was identified in only 43% of cases (17). Iron
eficiency was found in only 5% of patients. In the
emaining 57%, proinflammatory cytokine activation,
nadequate erythropoietin production, and/or defective
ron utilization was found despite adequate iron stores,
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August 12, 2008:501–11 Anemia and Chronic Heart Failureuggesting anemia of chronic disease (29). Therefore,
nemia of chronic disease could be the most frequent
ause of anemia during HF.
emodilution. Anemia might be due to hemodilution
25,46). Androne et al. (46) found that nearly one-half of
he clinically euvolemic patients referred for cardiac
ransplant had hemodilution induced “pseudoanemia.”
owever, others have found that clinically euvolemic
atients have normal plasma volume (47).
ompensatory mechanisms and pathophysiological con-
equences of anemia. Nonhemodynamic responses to ane-
ia include increase in erythropoiesis to enhance oxygen
arrying capacity, and increase in RBC 2,3-diphosphoglycerate
hat shifts the hemoglobin-oxygen dissociation curve to the
ight and improves oxygen delivery to the tissues (48). Because
rythropoiesis is defective in HF, hemodynamic responses may
redominate. In chronic severe anemia, low Hgb reduces
Figure 1 Possible Mechanisms Involved in the Genesis of Anem
Shown is a diagram of the possible mechanisms of anemia in patients with heart
seryl-aspartyl-lysyl-proline; ARB  angiotensin receptor blocker; DMT1  divalent m
ure; NF-B  nuclear factor-kappa B; RBC  red blood cell mass. Figure illustratioystemic vascular resistance (SVR) (49) as the result of de- mreases in blood viscosity and enhanced nitric oxide-mediated
asodilation (50,51). Low SVR reduces blood pressure (BP)
nd causes baroreceptor-mediated neurohormonal activation
49), identical to that seen in low output HF (31,52). The
ncreased sympathetic and renin-angiotensin activity decreases
BF and glomerular filtration rate, resulting in salt and water
etention by the kidneys and expansion of the extracellular and
lasma volumes. The combined effect of volume expansion and
asodilation increases the cardiac output (49), which may help
o increase oxygen transport (53). Correction of anemia in
atients with normal LV function causes a rapid and complete
egression of the syndrome of high output HF (49,51).
lthough these hemodynamic and neurohormonal responses
ere observed in patients with severe anemia, it is unclear
hether these mechanisms are also operative in HF patients
ith less severe anemia. However, similar changes have also
een reported in CKD patients with mild-to-moderate ane-
Heart Failure
. ACE-I  angiotensin-converting enzyme inhibitor; AcSDKP  N-acetyl-
ransporter 1; EPO  epoetin; GFR  glomerular filtration rate; HF  heart fail-
ob Flewell.ia in
failure
etal t
n by Ria. McMahon et al. (22) found that in patients with CKD,
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Anemia and Chronic Heart Failure August 12, 2008:501–11hen Hgb was increased progressively from 8.5 to 10 to 14
/dl with epoetin, the cardiac output (7.0 to 6.6 to 5.2 l/min)
nd the LV fractional shortening (36% to 33% to 29%)
ecreased significantly. Therefore, these data suggest that
orrection of anemia is unlikely to improve LV function.
he possible sequence of events in the pathogenesis of HF
n anemia is shown in Figure 2.
mplications of Anemia
nd Lower Hemoglobin on Outcomes
nemia and low Hgb have consistently been shown to be
ndependently associated with increased risk of mortality
nd hospitalizations for HF in acute and chronic HF with
V dysfunction. The data are summarized in recent reviews
6–8). Anemia increased the relative risk of death in these
tudies by 20% to 50%. A similar relationship has also been
hown in patients with preserved LV function (13–15,54).
ew-onset anemia and a decrease in Hgb over time are also
ssociated with increased mortality (9,10).
The association of Hgb with mortality is not linear, and
ost of the increased risk occurs at low Hgb concentrations
10,11,55). In Val-HeFT, the risk of death were nearly
dentical in the 2 upper Hgb quartiles, 13.7 to 14.7 g/dl
nd 14.7 g/dl, whereas increased risk was found in the
ower 2 Hgb quartiles (12.8 g/dl) and (12.8 to13.7 g/dl)
10). Some studies have reported a “J”-shaped relationship
Figure 2 Possible Sequence of Events Involved in the Pathogen
AVP  arginine vasopressin; GFR  glomerular filtration rate; LV  left ventricle;
RAA  renin-angiotensin-aldosterone. Data from Anand et al. (49). Figure illustratioetween Hgb and mortality in the normal population (56), tatients with coronary artery disease (57), acute coronary
yndromes (58), and HF (54,55). The lowest mortality risk
as observed in the Hgb range of 13 to 16 g/dl and the risk
ncreased with Hgb concentrations below or above this
ange. Thus, the concern that excessive increases in hemo-
lobin may be associated with increased mortality.
hy Is Anemia Associated With Poor Outcomes?
he increased myocardial workload due to hemodynamic
nd neurohormonal alterations observed in chronic anemia
49) could cause adverse LV remodeling. LV hypertrophy
nd dilation are observed in animal models of severe anemia
59,60), and they may contribute to poor outcomes.
hereas LV hypertrophy is consistently found in anemic
atients with CKD, it is unclear whether it is related to
nemia or hypertension (61). Although there are no data
irectly linking LV hypertrophy and anemia in HF, a 1-g/dl
ncrease in Hgb over the course of 24 weeks was associated
ith a 4.1-g/m2 decrease in LVmass in the RENAISSANCE
Randomized Etanercept North American Strategy to
tudy Antagonism of Cytokines) trial (19). However, treat-
ent of anemia with ESA does not reverse LV hypertrophy
n CKD (61). Hemoglobin may be inversely related to EF
10,15,22), and whereas anemia is related to brain natri-
retic peptide (BNP), a marker of LV dysfunction, anemia
emains an independent predictor of adverse outcomes in
of Heart Failure in Chronic Severe Anemia
ob Flewell.esis
n by Rhe presence of BNP and EF, suggesting that these variables
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August 12, 2008:501–11 Anemia and Chronic Heart Failureay have their effect through different mechanisms (10).
aken together, these findings suggest that changes in LV
tructure and function might not entirely explain the patho-
enesis of worse outcomes in anemia.
Chronic kidney disease is a common comorbidity in HF
atients with anemia (7,20), and both anemia and renal
ysfunction remain independent predictors of outcomes in
ultivariate models (10,15,20). The relative risk of death at
years was increased by a factor of 1.6 in anemic patients
ith heart failure who also had CKD in a large Medicare
atabase (62). In addition, anemia is often associated with
oor nutritional status, low albumin (10,15), and cardiac
achexia (63), all of which could worsen outcomes. Finally,
nemic patients have worse neurohormonal and proinflam-
atory cytokine profile that may also contribute to worse
utcomes (18,41,49). Thus, although anemia may be related
o a worse prognosis through multiple mechanisms, it is not
lear whether anemia is a mediator or just a marker of poor
utcomes.
reatment Options
ecause anemia is strongly associated with poor clinical
tatus and high mortality, it is logical to consider whether
orrecting anemia can improve outcomes. Only a few
ptions are available to increase Hgb. Although blood
ransfusion can be used as an acute therapy, transfusions are
ssociated with many risks and provide only temporary
enefit (64). The correction of hematinic abnormalities
ight help; however, most patients are thought to have
nemia of chronic disease, where stimulating erythropoiesis
ith ESAs is a rational strategy. Several small studies in HF
ave tested the effects of increasing Hgb with ESAs. Three
tudies investigated epoetin alfa, 1 study used epoetin beta,
nd 3 examined darbepoetin alfa (Table 1).
Silverberg et al. (65) were the first to report the effect of
poetin alfa and intravenous (IV) iron in 26 patients with
nemia and HF. An increase in Hgb was associated with
mprovements in NYHA functional class and LV ejection
raction and decreases in diuretic dose and hospitalizations.
year later, the same authors reported the result of another
tudy (66) in 32 patients with anemia and HF, randomized
o usual care (n  16) or epoetin alfa and IV iron sucrose (n
16) that confirmed the findings of the previous study.
lthough they are difficult to interpret because of the small
umber of patients studied and the uncontrolled open-label
esign, these pioneering studies lead to a great interest in
he treatment of anemia during HF.
Mancini et al. (67) conducted a patient-blind randomized
tudy in 26 HF patients with anemia and erythropoietin100
U/ml. Patients were randomized 2:1 to epoetin alfa plus oral
ron and folate, to increased hematocrit (Hct) to 45% or to
lacebo. After 3 months, Hgb, peak VO2, and 6-min walk
istance (6MWD) increased, and Minnesota Living with
eart Failure Questionnaire (MLHFQ) scores improved inreated patients with no changes in the placebo group. Re- sently, Palazzuoli et al. (68) reported the effects of epoetin beta
nd oral iron on LV structure and function, pulmonary artery
ressure, and BNP in 51 anemic HF patients with CKD (68).
atients were randomized to subcutaneous epoetin beta (n 
6) or saline (n  25) for 1 year. After 12 months, Hgb
ncreased; LV dimensions, volume, and mass decreased; and
F increased in the epoetin group with no change in the
ontrol group. The pulmonary artery pressure and BNP also
ecreased in the epoetin group.
A randomized, double-blind, placebo-controlled trial on 41
F patients with anemia and a peak VO2 16 ml/kg/min,
ssigned subjects to placebo (n 22) or darbepoetin alfa (n
9) for 26 weeks (69). Although the mean Hgb increased
ignificantly in the darbepoetin group, the mean changes in
eak VO2, exercise duration, Kansas City Cardiomyopathy
uestionnaire and MLHFQ scores, BNP, and renal function
ere not different between treatment groups. A multicenter,
ouble-blind placebo-controlled trial included 165 HF pa-
ients who were randomized to placebo (n  55) or darbepo-
tin given every 2 weeks for 26 weeks at a weight-adjusted (n
56) or fixed dose (n 54) (70). The increase in Hgb in the
ombined darbepoetin groups was associated with improve-
ent in Kansas City Cardiomyopathy Questionnaire total
ymptom score, but not in NYHA functional class, EF,
LHFQ score, 6MWD, or Patient’s Global Assessment
core. There were 6 deaths in the 110 darbepoetin and none in
he 55 placebo group. Other adverse events were similar
etween groups. STAMINA-HeFT (Study of Anemia in
eart Failure-Heart Failure Trial) is the third and largest study
n the darbepoetin program (71). In this multicenter, random-
zed double-blind placebo controlled study, 319 HF patients
ere randomized to darbepoetin and iron to maintain the Hgb
t 14.0  1.0 g/dl (n  162) or placebo (n  157) every 2
eeks for a year. At week 27, despite a significant increase in
gb, the primary end point of change from baseline in
readmill exercise time was not improved, nor was there any
mprovement in NYHA functional class or MLHFQ score
ompared with placebo.
A prespecified pooled analysis of the aforementioned 2
rials showed that compared with placebo, treatment with
arbepoetin was associated with a trend to lower composite
nd point of all-cause mortality or first HF-related hospi-
alization with hazard ratio (95% confidence interval) of
.67 (0.44 to 1.03), p  0.06, all-cause mortality 0.76 (0.39
o 1.48), p  0.42, and hospitalization for HF 0.66 (0.40 to
.07), p  0.09 (72). The incidence of other adverse events
ncluding development of hypertension and myocardial
nfarction were similar in the 2 groups.
In summary, analysis of all the published ESA trials in
F reveal that the early small-sized, single center studies
hat lacked a placebo-controlled arm showed a remarkable
mprovement in clinical status and LV function when ESA
as used to treat anemia. However, the 3 more recent
ouble blind, placebo-controlled, randomized trials with
arbepoetin showed less impressive results. Erythropoietin-
timulating agents were generally well tolerated in the HF
Summary of All Published Studies That Have Tested the Effects of Erythropoietin-Stimulating Agents in Anemic Patients With HF
Table 1 Summary of All Published Studies That Have Tested the Effects of Erythropoietin-Stimulating Agents in Anemic Patients With HF
Author,
Year (Ref. #) Study Design Inclusion Criteria
Patients
(n)
Follow-Up
Duration
(months)
Baseline
Hgb
(g/dl)
Target
Hgb
(g/dl)
Achieved Hgb
(g/dl)
Agents and
Dose Used Outcomes
Silverberg et al.,
2000 (65)
Single-center,
uncontrolled,
open-label
EF 35, Hgb 12 g/dl 26 7.2 5.5 10.2 12.0 12.1 S/C epoetin alfa (mean
5,277 IU/week)  IV
iron sucrose (mean
185 mg/month)
2NYHA functional class (3.7  0.5 to 2.7  0.7,
p  0.05),1LVEF (28  5% to
35  8%, p  0.001)
Decrease in diuretic dose
Decrease in hospitalizations
Silverberg et al.,
2001 (66)
Single-center,
randomized,
no placebo,
open-label
NYHA functional class
III/IV, EF 40%,
Hgb 10–11.5 g/dl
16 usual care,
16 EPO
8.2 2.6 10.3 12.5 12.9 S/C epoetin alfa (4,000
IU 1–3 week) IV iron
sucrose (200 mg/2
weeks)
2NYHA functional class,1LVEF 5.5%
Decrease in diuretic dose
Decrease in hospitalizations
Mancini et al.,
2003 (67)
Single-center,
single-blind,
randomized,
placebo-controlled
NYHA functional class
II/IV, Hct 35%,
9 control, 17 EPO 3.0 11.0 0.6 Hct 45% 14.3 1.2 S/C epoetin alfa 15,000
to 30,000 IU/ week 
oral iron 325 mg and
folate 1 mg OD
1Peak VO2 11 0.8 to 12.7 2.8 ml/kg/min
(p  0.05),16MWD
Improvement in MLHFQ
Palazzuoli et al.,
2007 (68)
Single-center,
randomized,
double-blind,
placebo-controlled
NYHA functional class
III/IV, EF 40%,
Hgb 9.0–12.0 g/dl,
serum creatinine
1.5–3.0 mg/dl
25 control,
26 beta EPO
12 10.4 0.6 NA 12.4 0.8 S/C epoetin beta 6,000
IU/2 week  oral iron
300 mg for 1 year
1LVEF,2LV volumes, mass2PAP and BNP
No change in serum creatinine
Ponikowski et al.,
2007 (69)
Multicenter,
randomized,
double-blind,
placebo-controlled
Hgb 9.0–12.0 g/dl,
peak VO2 16
ml/kg/min
22 placebo,
19 darbepoetin
27 weeks 11.8 0.2 13.0–15.0 13.9 0.4 Darbepoetin alfa, 0.75
g/kg Q2W 
200–300 oral iron if
serum ferritin
800 ng/ml
Mean change in peak Vo2 (45 ml/min,
p  0.27) or (0.5 ml/kg/min, p  0.40)
Ex duration 108 s (p  0.08),1PGA
(79% vs. 41%, p  0.01)
No change in KCCQ/MLHFQ
No change in BNP or Cr
van Veldhuisen et al.,
2007 (70)
Multicenter,
randomized,
double-blind,
placebo-controlled
Hgb 9.0 and
12.5 g/dl, NYHA
functional class II/III
CHF, LVEF 40%
55 placebo,
56 darbepoetin
(weight based),
and 54
darbepoetin
(fixed dose)
27 weeks 11.5 14 1.0 13.3 Darbepoetin weight
adjusted 0.75 g/kg
vs. fixed dose 50 g
vs. placebo Q2W 
oral iron (200 mg OD
if serum ferritin
800 ng/ml)
Rate of rise Hgb 1.87 vs. 1.64 g/dl in weight-
based vs. fixed dose (p  0.07), improvement
in KCCQ (p  0.03), no significant
improvement in 6MWD (p  0.074), patients
global assessment (p  0.057), NYHA
functional class, LVEF, or MLHFQ score
Ghali et al., 2008
(STAMINA-HeFT)
(71)
Multicenter,
randomized,
double-blind,
placebo-controlled
Hgb 9.0 and
12.5 g/dl, NYHA
functional class II/IV
CHF, LVEF 40%,
157 placebo,
162 darbepoetin
27 weeks for
efficacy 55
weeks for
safety
11.4 14 1.0 13.4 at
27 weeks,
13.4 at
53 weeks
Darbepoetin dose 0.75
g/kg Q2W vs. placebo
 oral iron (200 mg OD
if serum ferritin
800 ng/ml)
No significant difference in exercise duration,
NYHA functional class or quality of life scores
at 27 weeks but trend to a decrease in the
combined end point of death and
hospitalization for HF
van Veldhuisen and
McMurray 2007
(72)
Combined safety
analysis
Hgb 9.0 and
12.5 g/dl, NYHA
functional class II/III
CHF, LVEF 40%
209 placebo,
266 darbepoetin
55 weeks 11.4 0.8 14 1.0 13.4 Darbepoetin dose 0.75
g/kg or 50 g vs.
placebo Q2W  oral
iron (200 mg OD
if serum ferritin
800 ng/ml)
Trend to a decrease in the combined endpoint of
death and hospitalization for HF (hazard ratio)
and 95% confidence interval) for darbepoetin
vs. placebo 0.67 (0.44 to 1.03), p  0.06
CHF  congestive heart failulre; EF  ejection fraction; EPO  epoetin; Hct  hematocrit; HF  heart failure; Hgb  hemoglobulin; IV  intravenous; KCCQ  Kansas City Cardiomyopathy Questionnaire; LV  left ventricular; MLHFQ  Minnesota Living with Heart Failure
Questionnaire; NYHA  New York Heart Association; OD  once daily; PAP  systolic pulmonary artery pressure; PGA  Patient’s Global Assessment; Q2W  every 2 weeks; S/C  subcutaneous; 6MWD  6-min walk distance.
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August 12, 2008:501–11 Anemia and Chronic Heart Failureatients with no significant increase in cardiovascular or
ther complications reported in the CKD and cancer
opulation (73).
re There Risks of Increasing
emoglobin With ESA Therapy?
he second National Kidney Foundation Kidney Disease
utcomes Quality Initiative anemia guidelines recom-
ended use of erythropoietin in CKD patients to a target
gb of 11 to 13 g/dl to avoid blood transfusions and
mprove quality of life (74). In the 1990s, several trials were
onducted to assess whether complete normalization of Hgb
ould produce additional benefits. The NHCT (Normal
ematocrit Cardiac Trial) study randomized 1,223 CKD
emodialysis patients to receive epoetin alfa to achieve a Hct
f 45% versus 30% (75). The study was terminated early
ecause of a trend to increased risk of the composite of
eath or nonfatal MI and greater incidence of vascular
ccess thrombosis in the normal Hct group (39% vs. 29%,
 0.001). More recently, 2 publications—CREATE
Cardiovascular Risk Reduction by Early Anemia Treat-
ent with Epoetin Beta) (76) and CHOIR (Correction of
emoglobin and Outcomes in Renal Insufficiency) (77)—
ave raised real concerns about the cardiovascular safety of
reater Hgb with the use of ESAs in CKD patients. In
REATE, 603 patients (Hgb 11.6  0.6 g/dl) were
andomized to epoetin beta to normalize Hgb (13.0 to 15.0
/dl) or use of epoetin only if Hgb decreased to 10.5 g/dl.
here was a trend to increased mortality relative risk of 34%
p  0.14) with the greater Hgb. In CHOIR, researchers
andomized 1,432 patients (Hgb 10.1  0.9 g/dl) to receive
poetin to achieve an Hgb of 13.5 or 11.3 g/dl. The trial
as stopped early for presumed futility but showed a 34%
p  0.03) increase in the composite of death, myocardial
nfarction, hospitalization for HF, and stroke in the high
gb group.
There are significant limitations with these trials, partic-
larly CHOIR, regarding imbalance of cardiovascular dis-
ase at baseline, issues of dropout, and the use of high doses
f erythropoietin (78). Nevertheless, a meta-analysis of 9
andomized trials, including the 3 mentioned previously,
hat compared different target Hgb concentrations (73),
ound an increase in all-cause mortality relatively by 17%
p  0.03), arteriovenous access thrombosis by 34% (p 
.0001) and poorly controlled BP by 27% (p 0.004) in the
igh Hgb group. Therefore, until definitive data are avail-
ble from well-conducted trials, clinicians should refrain
rom complete correction of anemia.
Researchers for the TREAT (Trial to Reduce Cardiovas-
ular Events with Aranesp Therapy) study, a 4,000-patient,
ulticenter, double-blind, placebo-controlled trial in pa-
ients with CKD and type 2 diabetes mellitus, have com-
leted enrollment (79). Subjects are randomized to either
arbepoetin to a target Hgb of 13 g/dl or placebo and
arbepoetin for Hgb 9 g/dl until Hgb is 9 g/dl. The erimary end point is the time to mortality and nonfatal
ardiovascular events. The accumulated safety database in
REAT already exceeds all previous ESA trials, and the
ata Safety Monitoring Board has not recommended any
hange in its conduct (80). The results of TREAT are likely
o provide definitive information regarding the role of ESAs
n the management of patients with anemia and CKD.
Meanwhile, on the basis of all the safety data from ESA
herapy, the Food and Drug Administration updated the
black box warning” in the prescribing information for all
SAs in November 2007 and revised the dosing recommen-
ations for anemic patients with CKD to maintain Hgb
ithin 10 to 12 g/dl to avoid use of blood transfusion, and
emoved the previous quality of life claim (81).
echanisms of the Observed
dverse Effects in CKD Patients
he greater risk of developing poorly controlled BP in CKD
atients randomized to achieve higher Hgb with ESAs (73)
ould have contributed to worse cardiovascular events.
ncrease in BP at higher Hgb is explained on increased
iscosity and reduced nitric oxide availability (49,51). Other
ossible mechanisms include increase in vascular cytosolic
alcium (82), and endothelin-1 and tissue-specific renin-
ngiotensin activity (83,84) associated with erythropoietin
se. Greater viscosity and erythropoietin associated antifi-
rinolytic activity may increase thrombotic risk (85).
Correcting anemia in HF is a tradeoff between the
avorable effects of improving oxygen delivery and unfavor-
ble effects of increasing viscosity and SVR on the BP,
ardiac output and LV function. An increase in Hgb is
ssociated with reduction in EF and an increase in BP
22,49,51). Hence, correction of anemia is unlikely to have
beneficial effect on LV function or hemodynamics. How-
ver, the small uncontrolled trials reported an increase in
F, and no increase in BP or thrombotic events were
bserved in any trial (65–68). Whether the potential benefit
f correcting anemia are outweighed by harm can only be
esolved with prospective, double-blind, placebo-controlled
andomized controlled trials. Darbepoetin alfa is currently
eing tested in the RED-HF (Reduction of Events with
arbepoetin alfa in Heart Failure) trial, a large-scale, phase
II morbidity and mortality trial (72). The results of this
rial are likely to provide important information on the
afety and efficacy of ESAs in patients with anemia and HF.
onerythropoietic Effects of ESA
rythropoietin receptors are also present on the neurons,
ardiomyocytes, and endothelial cells (86). Several studies
ave confirmed that ESAs decrease experimental infarct
ize, reduce hypoxic injury, prevent myocyte apoptosis, and
obilize endothelial progenitor cells, independent of in-
reases in Hgb (87–89). It is therefore possible that the
eneficial effects of ESA are related to their nonhemopoietic
ffects and not to an increase in Hgb. These findings have
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Anemia and Chronic Heart Failure August 12, 2008:501–11ead to the design of 2 phase II studies, one in the U.S. (90)
nd another in Europe (91), to examine the effect of an ESA
n LV structure and function in post-myocardial infarction
atients.
Recently, a second receptor for erythropoietin that me-
iates tissue protection has been identified consisting of the
ommon  receptor subunits, also known as CD 131, that
s not within the erythropoietin receptor-binding domain
nd is present in the myocardium (92). Modification of
rythropoietin by carbamylation of all its lysines to homo-
itrulline carbamylated erythropoietin caused the compound
o completely lack erythropoietic activity but retain tissue
rotection (93). Carbamylated erythropoietin has been
hown to prevent ischemia/reperfusion related apoptosis
fter myocardial infarction in vivo and in isolated cardio-
yocytes in vitro (94). These agents could potentially
rovide myocardial protection in HF without the undesir-
ble effects of erythropoietin. At present, there are no
linical data in HF.
reatment of Anemia Using Iron Alone
s discussed previously, either relative or absolute iron
eficiency is frequently found in anemic HF patients. Iron is
ssential not only for erythropoiesis but also for several
nzyme-linked bioenergetic processes in the skeletal muscle
nd in the Krebs cycle (95). Chronic iron deficiency may, by
tself, reduce exercise capacity (96) and cause ultrastructural
lterations in the cardiac myocytes (97). Therefore, IV iron
lone may be beneficial in iron-deficient, anemic or non-
nemic HF patients. Three studies have tested this hypoth-
sis in patients with iron deficiency defined by transferrin
aturation and ferritin levels. In an uncontrolled open-label
tudy in 16 anemic (Hgb 12 g/dl) HF patients with iron
eficiency in 44% of patients, IV iron sucrose was given for
2 to 17 days, and patients were followed for 92  6 days
98). Iron treatment increased Hgb from 11.2  0.7 g/dl to
2.6  1.2 g/dl (p  0.0007) and improved NYHA
unctional class, MLHFQ score, and 6MWD. The second
tudy was a randomized, double-blind, placebo-controlled
rial in 40 anemic HF patients (99). Control subjects (n 
0) received IV saline whereas the treatment group was
iven 200 mg of IV iron sucrose weekly for 5 weeks. After
months, Hgb increased by a mean of 1.4 g/dl (p  0.01),
nd there was an improvement in creatinine clearance and
LHFQ score, decrease in CRP and N-terminal-proBNP,
nd increase in EF and 6MWD in the IV iron but not
lacebo group. The FERRIC-HF (Ferric iron sucrose in
eart Failure) (100) trial evaluated exercise capacity in
ron-deficient anemic and nonanemic, HF patients with
eak VO2 18 ml/kg/min. Eighteen anemic (Hgb 12.5
/dl) and 17 nonanemic (Hgb 12.5 to 14.5 g/dl) patients
ere randomized to open-label, observer-blinded treatment
ith placebo or intravenous iron sucrose 200 mg/week for 4
eeks and then 200 mg/month for 3 months. Iron therapy
ncreased serum ferritin and improved NYHA functional dlass but, unlike the previous 2 studies, Hgb did not
ncrease. Peak VO2 increased significantly in the anemic but
ot in the nonanemic group. Although these 3 small
nderpowered studies raise the possibility that iron therapy
lone may have a role in anemic patients with HF, large
andomized placebo-controlled trials are required to con-
rm these intriguing findings. One such trial, IRON-HF
Iron Supplementation in Heart Failure Patients With
nemia), is in progress (101).
It must be emphasized that iron therapy is not without
isks and has been associated with the risk of developing
acteremia (102). Moreover, iron therapy in the setting of
mmune activation may promote highly toxic hydroxyl
adicals that can cause tissue damage and endothelial dys-
unction, and increase the risk of adverse cardiovascular
utcomes (103).
mplication for Clinicians
one of the HF clinical practice guidelines from the U.S. or
urope currently discuss the assessment and management of
nemia in HF. Given current evidence, the use of ESA and
upplemental iron should only be considered in patients
ith concomitant CKD. The National Kidney Foundation
DOQI clinical practice guideline were updated in 2007
fter publication of CREATE and CHOIR trials and
ecommend use of ESA to achieve a Hgb target in the range
f only 11.0 to 12.0 g/dl (104). With the removal of the
uality of life claim by the Food and Drug Administration,
he only claim for the use of ESA is to improve exercise
olerance and functional ability of CKD patients (81). In
F patients, even these have not been convincingly shown
o improve. Therefore, until long-term clinical outcomes
ata are available in HF patients with anemia, the use of
SA is not recommended in anemic patients with HF who
o not have a CKD indication for its use.
onclusions
nemia is a common comorbidity in patients with HF and
s associated with worse long-term outcomes. Although the
ause of anemia in HF is unclear, the weight of evidence
uggests that renal dysfunction and neurohormonal and
roinflammatory cytokine activation in HF favor the devel-
pment of anemia of chronic disease. Similarly, the mech-
nisms by which anemia worsens HF outcomes are un-
nown but may be related to increased myocardial
orkload. Although anemia is a rational therapeutic target
o improve outcomes, there are as yet no convincing data
egarding the efficacy and long-term safety of ESA. Further
tudies are required to understand the basis of the remark-
ble association of anemia with HF outcomes, to prospec-
ively assess the potential benefit of correcting anemia, to
valuate the ideal threshold at which therapy should be
nitiated, and the extent of correction considered safe and
esirable. Two large mortality morbidity trials, TREAT in
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ay be able to provide answers to some of these questions.
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